Meeting Overview:

The ISPOR Asia Consortium Industry Committee is hosting a virtual meeting that will bring together stakeholders interested in health technology innovation and health policy in the Asia Pacific region, to connect and learn about healthcare hot topics. The meeting features two marquee presentations followed by a Q and A session. Professor Xin Sun of Sichuan University will discuss how to use real-world evidence (RWE) for China's regulatory and reimbursement decision making and Dr. Ying-Li (Tommy) Chen from Centre for Drug Evaluation will share the Taiwanese experience in applying managed entry agreements and RWE to support health policy development. The meeting is open to all interested in learning more. Please join us for a great learning event!

Date and Time:

Wednesday, 29 June 2022, 8:00AM-9:00AM US Eastern Time (Time Conversion)

Intended audience: 

This complementary meeting is open to all interested in learning about health policy and HEOR in the Asia Pacific region.

Featured Presentations:

• Use of RWE for Regulatory and Reimbursement Decisions in China

• Experience and Lessons Learned: Utilizing Managed Entry Agreements and Real-World Evidence in Taiwan’s Health Policy

Speakers:

• Xin Sun, PhD, Professor and Director, Chinese Evidence-based Medicine Center, West China Hospital of Sichuan University, Chengdu, China
• Ying-Li (Tommy) Chen, BS Pharmacy, MHS in Health Economics, Board of Director of HTAsiaLink and HTA Researcher of Center for Drug Evaluation (CDE), Taipei, Taiwan
• Sang-Soo Lee, PhD, MBA, Chair of ISPOR Asia Consortium Industry Committee and Sr. Director of Health Care Economics and Government Affairs, Medtronic, North Asia (Korea and Japan), Seoul, South Korea

Registration:

To register for this event, please visit here.